On March 3, 2023 Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, reported that data for its lead oncogenic driver candidate targeting KRAS G12V, AFNT-111, will be presented at the AACR (Free AACR Whitepaper) Special Conference: Targeting Ras (Press release, Affini-T Therapeutics, MAR 3, 2023, View Source [SID1234628127]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to see encouraging data from preclinical studies of AFNT-111 as we progress toward clinical investigation," said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. "We have observed high potency and specificity as well as a favorable tolerability profile, which provides encouraging support for our oncogenic driver programs. We look forward to presenting these data at the AACR (Free AACR Whitepaper) Special Conference: Targeting Ras in Philadelphia."

Presentation details are as follows:

Abstract #A009, Poster Session A: March 6th 4:45-7:00 pm ET: AFNT-111: a novel TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V – Presenting Authors: Gary Shapiro, Ph.D. and Michele Hoffmann, Ph.D., Affini-T Therapeutics